{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:33:32Z","timestamp":1781904812423,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1053\/j.ajkd.2021.12.015","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T12:45:27Z","timestamp":1645706727000},"page":"555-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Zoledronic Acid\u2013Associated Fanconi Syndrome in Patients With Cancer"],"prefix":"10.1053","volume":"80","author":[{"given":"Ignacio","family":"Portales-Castillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Mount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U.","family":"Nigwekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine W.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut G.","family":"Rennke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2021.12.015_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/ajkd.2003.50037","article-title":"Drug-induced Fanconi\u2019s syndrome","volume":"41","author":"Izzedine","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2021.12.015_bib2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"issue":"23","key":"10.1053\/j.ajkd.2021.12.015_bib3","first-page":"232","article-title":"Transient renal tubular dysfunction following zoledronic acid treatment","volume":"23","author":"Gnanadeepan","year":"2020","journal-title":"Ann Trop Med Public Health"},{"issue":"6","key":"10.1053\/j.ajkd.2021.12.015_bib4","first-page":"660","article-title":"Kidney failure caused by tubular intersticial nephropathy with Fanconi syndrome after treatment with zoledronic acid","volume":"37","author":"Gutierrez Sanchez","year":"2017","journal-title":"Nefrolog\u00eda"},{"issue":"7","key":"10.1053\/j.ajkd.2021.12.015_bib5","first-page":"867","article-title":"A\u00a0case of Fanconi syndrome induced by zoledronic acid in a metastatic colorectal cancer patient [in Japanese]","volume":"42","author":"Okagawa","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3","key":"10.1053\/j.ajkd.2021.12.015_bib6","first-page":"184","article-title":"Fanconi syndrome related to zoledronic acid","volume":"33","author":"Oliveira","year":"2019","journal-title":"Port J Nephrol Hypertens"},{"issue":"12","key":"10.1053\/j.ajkd.2021.12.015_bib7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1507\/endocrj.EJ12-0166","article-title":"A\u00a0case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome","volume":"59","author":"Torimoto","year":"2012","journal-title":"Endocr J"},{"issue":"9","key":"10.1053\/j.ajkd.2021.12.015_bib8","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2169\/internalmedicine.50.4855","article-title":"A\u00a0case of acquired Fanconi syndrome induced by zoledronic acid","volume":"50","author":"Yoshinami","year":"2011","journal-title":"Intern Med"},{"issue":"5","key":"10.1053\/j.ajkd.2021.12.015_bib9","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"issue":"1","key":"10.1053\/j.ajkd.2021.12.015_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2021.12.015_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2005.pto_160.x","article-title":"Acute renal effects of intravenous bisphosphonates in the rat","volume":"97","author":"Pfister","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.12.015_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121861","article-title":"Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound","volume":"10","author":"Verhulst","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.ajkd.2021.12.015_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00204-017-2048-0","article-title":"Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity","volume":"92","author":"Cheng","year":"2018","journal-title":"Arch Toxicol"},{"issue":"3","key":"10.1053\/j.ajkd.2021.12.015_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1574886311666160426141647","article-title":"Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern","volume":"11","author":"Kaur","year":"2016","journal-title":"Curr Drug Saf"},{"issue":"12","key":"10.1053\/j.ajkd.2021.12.015_bib15","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.20290","article-title":"Gemcitabine-associated thrombotic microangiopathy","volume":"100","author":"Humphreys","year":"2004","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.ajkd.2021.12.015_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor\u2013associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2021.12.015_bib17","article-title":"Immune checkpoint inhibitor-induced Fanconi syndrome","volume":"12","author":"Farid","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"10.1053\/j.ajkd.2021.12.015_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.xkme.2020.05.015","article-title":"Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor\u2014a report of 3 cases","volume":"2","author":"Herrmann","year":"2020","journal-title":"Kidney Med"},{"issue":"1","key":"10.1053\/j.ajkd.2021.12.015_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ckj\/sfz051","article-title":"A\u00a0new expression of immune checkpoint inhibitors\u2019 renal toxicity: when distal tubular acidosis precedes creatinine elevation","volume":"13","author":"Charmetant","year":"2020","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ajkd.2021.12.015_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000185243","article-title":"Renal tubular dysfunction in pancreatic cancer and chronic pancreatitis","volume":"51","author":"Fabris","year":"1989","journal-title":"Nephron"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622005157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622005157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:43:13Z","timestamp":1759462993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622005157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0272638622005157"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.12.015","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic Acid\u2013Associated Fanconi Syndrome in Patients With Cancer","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2021.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}